Target intelligence / Profile preview

Pathogenic Escherichia coli (E. coli (when referring to the species; no unique abbreviation for "pathogenic" forms))

Target
E. coli (when referring to the species; no unique abbreviation for "pathogenic" forms)
Molecular classification
Bacterium, Gram-negative bacterium, Enterobacteriaceae family member, Other
01

Overview

Pathogenic *Escherichia coli* refers collectively to those strains of *E. coli* that possess specific virulence factors enabling them to cause disease in humans or animals. While most *E. coli* are harmless commensals found in the gut flora of warm-blooded animals and humans, pathogenic variants can cause a range of diseases including gastroenteritis/diarrhea (e.g., enteropathogenic [EPEC], enterohemorrhagic [EHEC]/Shiga toxin-producing [STEC]), urinary tract infections (uropathogenic [UPEC]), neonatal meningitis, and sepsis. These bacteria are gram-negative rods belonging to the family Enterobacteriaceae and can be transmitted via contaminated food or water or person-to-person contact through fecal–oral routes. Pathogenesis depends on strain-specific mechanisms such as production of toxins—most notably Shiga toxins in STEC/EHEC—adherence factors that allow colonization and damage to host tissues, immune evasion strategies, and sometimes invasion beyond the gut mucosa leading to systemic disease. The term "Pathogenic Escherichia coli" is not a single molecular target but rather a broad category encompassing multiple pathotypes defined by their distinct virulence genes and clinical syndromes; thus it does not refer to one specific molecule/receptor but rather an entire group/species with diverse targets within it. **Note:** The entry "Pathogenic Escherichia coli" is **not** a single molecular target such as an enzyme or receptor but instead refers broadly to any disease-causing strain within the species *Escherichia coli*. For structured drug discovery databases focused on molecular targets rather than pathogens/species-level entries this would be considered **incorrect** ([is_incorrect]: true). If you require information about a specific virulence factor/protein from these bacteria—such as Shiga toxin or intimin—it would be more appropriate to specify that molecule directly.

Other names
Enteropathogenic Escherichia coliEPECShiga toxin-producing Escherichia coli (STEC)enterohemorrhagic Escherichia coli (EHEC)uropathogenic Escherichia coli (UPEC)extraintestinal pathogenic E. coli (ExPEC)intestinal pathogenic E. colidiarrheagenic E. coli
02

Mechanism of action

Inhibition of bacterial cell wall synthesis or protein synthesis by antibiotics. For STEC/EHEC infections specifically, supportive care is primary as antibiotics may worsen outcomes by increasing toxin release.

03

Biological functions

Pathogenesis of infectionToxin productionAdherence to host cellsImmune evasion
04

Disease associations

Infection - Gastroenteritis/diarrhea/food poisoningInfection - Urinary tract infectionInfection - MeningitisInfection - Sepsis/septic shockInfection - Hemolytic uremic syndrome (HUS)
05

Safety considerations

Risk of severe complications such as hemolytic uremic syndrome with certain strains like O157:H7/STEC if treated with inappropriate antibiotics.Increasing antibiotic resistance among clinical isolates.
06

Interacting drugs

Antibiotics such as fluoroquinolones, cephalosporins, aminoglycosides, carbapenems; however, antibiotic use is controversial in some cases like STEC due to risk of HUS development and resistance concerns.
07

Biomarkers

Detection of Shiga toxins in stool samples for STEC/EHEC diagnosis.Serotyping for O157:H7 and other virulent strains.

Beyond the preview

Go deeper on Pathogenic Escherichia coli (E. coli (when referring to the species; no unique abbreviation for "pathogenic" forms)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic Escherichia coli (E. coli (when referring to the species; no unique abbreviation for "pathogenic" forms)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call